A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome

Inclusion Criteria:

- RR-AML

- Relapsed/refractory MDS

- Participants with a history of allogeneic stem cell transplant are eligible for study
participation provided the following eligibility criteria are met:

1. Transplant was more than (>) 100 days prior to study enrollment

2. Participant has not taken immunosuppressive medications for at least 2 weeks

3. No signs or symptoms of graft versus host disease other than Grade 1 skin
involvement

4. No active infection

- Eastern Cooperative Oncology Group Performance Status score equal to or less than (<=)
2

- Life expectancy of at least 2 months

- Disease-free of active second/secondary or prior malignancies for equal to or more
than (>=) 1 year with the exception of currently treated basal cell or squamous cell
carcinoma of the skin, or carcinoma in-situ of the cervix or breast

- Adequate hematological, renal, hepatic and coagulation laboratory test results

- Women of childbearing potential and men must agree to use adequate contraception from
28 days prior to the first dose of the study drug, during the entire Treatment Period,
and for at least 28 days after the last dose of the study drug

Exclusion Criteria:

- New York Heart Association Class III or IV cardiac disease, myocardial infarction
within the past 6 months, unstable arrhythmia

- Have Fridericia-corrected QT interval > 470 milliseconds (msec) (female) or > 450 msec
(male), or history of congenital long QT syndrome

- Uncontrolled bacterial, viral, or fungal infections

- Known clinically important respiratory impairment

- Positive for human immunodeficiency virus, hepatitis B surface antigen, or hepatitis C
antibodies

- History of major organ transplant

- Symptomatic central nervous system disease, malignancy, or metastasis

- Pregnant or nursing

- Concomitant chemotherapy, radiation therapy, immunotherapy, biologic therapy, or
hormonal therapy

- Treatment with surgery or chemotherapy within 21 days prior to study entry

- Prior treatment with small molecule bromodomain and extra terminal family inhibitor

- Radiation for symptomatic lesions within 14 days of study enrollment

- Active substance abuse